Stay updated with the latest good-manufacturing-practice news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on good-manufacturing-practice topics.
Granules Life Sciences (GLS) manufacturing facility in Shamirpet, near Hyderabad, has been classified as voluntary action indicated (VAI) by the U.S. Food and Drug Administration (U.S. FDA) consequent to an inspection in December 2025. The establishment inspection report (EIR) was issued following a current good manufacturing practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations between December 15 and 19. The inspection is now closed and no regulat ...Read More >
India's biotech ecosystem has also expanded significantly, now comprising over 2,500 startups, around 100 incubators, more than 600 research institutes, and over 200 accredited laboratories India's biotech sector is entering a new phase of global relevance, with the country's bioeconomy expanding from $10 billion in 2014 to $195 billion in 2026 and projected to touch nearly $300 billion by 2033, according to a report by Endiya Partners. The report, India's Biopharma Moment: Perspectives from D ...Read More >
Hyderabad : Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated (VAI). The Establishment Inspection Report (EIR) was issued following a current Good Manufacturing Practice (cGMP) and pre approval inspection (PAI) of the oral solid dosage manufacturing operations conducted ...Read More >
India's tobacco sector is a double-edged sword: it sustains 45.7 million livelihoods while fueling a public health crisis that kills prematurely and burdens the economy. Our Civitas white paper identifies a "development trap" -- a self-reinforcing cycle in which economic dependence on informal production of tobacco thwarts effective control, leaving 266.8 million users, primarily SLT (Smokeless Tobacco) and beedi consumers, without adequate cessation support while exposing workers to precarious ...Read More >
New Delhi, March 31 (SocialNews.XYZ) India's bioeconomy is approaching the $200 billion mark, which is a significant milestone in its evolution with a strong policy push and growing innovation pipeline signalling the next phase of growth, according to a report released on Tuesday. The report by Endiya Partners said that the nation's bioeconomy has expanded sharply from around $10 billion in 2014 to over $195 billion in 2026, now contributing nearly 5 per cent to the GDP. India, long recognised ...Read More >
Mumbai (Maharashtra) [India], March 31: Rusan Healthcare Pvt. Ltd., the marketing and distribution arm of Rusan Pharma Limited, an integrated global pharmaceutical company, has announced the launch of the multi-dose delivery pen device - APOSAN® 3ml Pen (Apomorphine Hydrochloride solution for injection in cartridge)(10mg/ml)(3ml pre-filled cartridges) for treatment of motor fluctuations commonly known as 'ON-OFF' episodes in patients suffering from Parkinson's disease (PD). Also Read | Ashok Kh ...Read More >
Bhubaneswar: The Odisha government Tuesday unveiled Pharmaceutical and Medical Devices Policy-2025, aiming to attract investment of Rs 25,000 crore and create 1 lakh jobs by 2030. Chief Minister Mohan Charan Majhi launched the new policy here at the Odisha Pharma Summit-2025 in the presence of Industries Minister Sampad Chandra Swain and senior government officers. Speaking on the occasion, Industries Department's Additional Chief Secretary Hemant Sharma said India imports about 85 per cent of ...Read More >
NEW DELHI: India's drug regulator has sought strict compliance with revised Schedule M. It has asked state drug regulators to carry out inspections of pharma manufacturing units which have applied for extension of Schedule M to verify their compliance with the requirements, in a bid to ensure quality of pharma products by mandating Good Manufacturing Practices (GMP). "In case any manufacturing unit is found non-complying to the requirements of revised Schedule M during inspections, strict actio ...Read More >
Dr Reddy's Laboratories has received a report from the US Food and Drug Administration. The report concerns its manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA has classified the inspection outcome as Voluntary Action Indicated. This means the inspection is officially closed. The company received the Establishment Inspection Report on October 20, 2025. Drugmaker Dr Reddy's Laboratories Ltd on Tuesday said it has received establishment inspection report from the US health regulat ...Read More >
The Union health ministry addressed cough syrup quality. A meeting reviewed drug norm compliance. This followed child deaths linked to syrups in Chhindwara and Rajasthan. States received advice on cough syrup use for children. One cough syrup, Coldrif, contained DEG beyond limits. Action occurred against the manufacturer. Inspections began across 19 units. Officials urged adherence to manufacturing practices. Amid concerns over the quality of cough syrups, the Union health ministry on Sunday un ...Read More >
Cohance Lifesciences will be investing ₹23 crore (₹230 million) in its new Current Good Manufacturing Practice (cGMP) oligonucleotide building block manufacturing facility in Hyderabad. "Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality and flexibi ...Read More >
Glenmark Pharmaceuticals disclosed receiving a warning letter from the U.S. FDA for its Indore facility following a February inspection. The company clarified that the letter won't impact existing supplies or revenues. It also emphasized its commitment to compliance and noted no data integrity issues were found. Glenmark Pharmaceuticals shares may be in focus on Monday, July 14, after the company disclosed that it has received a warning letter from the U.S. Food and Drug Administration (FDA) fo ...Read More >
New Delhi, India - The quest for thicker, healthier hair has led many down a path of serums, supplements, and even surgical procedures. But a cutting-edge treatment utilizing microscopic "bubbles" called exosomes is emerging as a potential game-changer. Exosomes are tiny vesicles released by cells, acting as messengers carrying proteins and genetic material to other cells. This natural interaction system has sparked interest in the field of regenerative medicine, with exosome therapy showi ...Read More >
Granules India shares slipped sharply in trade, down nearly 10% after the company informed that US FDA has classified the inspection at Gagillapur facility in Hyderabad, Telangana as an 'Official Action Indicated' (OAI). The exchanges were informed about an inspection at the facility on September 7, which had resulted in a Form 483 issuance with six observations. Now, Granules India has said that it has responded to 'all the observations' issued by the USFDA. "The Company has responded to all ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.